The expression of drug resistance gene products during the progression of human prostate cancer

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1393-1403

  Sullivan, Gregory F ^a,b   Amenta, Peter S ^a,b   Villanueva, Jocelyn D ^a   Alvarez, Carmelita J ^a   Yang, Jin Ming ^a,b   Hait, William N ^a,b,c  

^a UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLUTATHIONE TRANSFERASE;

APOPTOSIS; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL VIABILITY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; ODDS RATIO; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031749970     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Ismail, M., and Gomella, L. G. Current treatment of advanced prostate cancer. Tech. Urol., 3: 16-24, 1997.
2. Newling, D. W. The management of hormone refractory prostate cancer. Eur. Urol., 29 (Suppl. 2): 69-74, 1996.
3. Lutzker, S. G., and Levine, A. J. Apoptosis and cancer chemotherapy. Cancer Treat. Res., 87: 345-356, 1996.
4. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
5. Schulze, H., and Isaacs, J. T. Biology and therapy of prostatic cancer. Cancer Surv., 5: 487-503, 1986.
6. Cookson, M. S., Reuter, V. E., Linkov, I., and Fair, W. R. Glutathione S-transferase π (GST-π) class expression by immunohistochemistry in benign and malignant prostate tissue. J. Urol., 157: 673-676, 1997.
7. Murray, G. I., Taylor, V. E., McKay, J. A., Weaver, R. J., Ewen, S. W., Melvin, W. T., and Burke, M. D. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J. Pathol., 177: 147-152, 1995.
8. Stattin, P., Damber, J. E., Karlberg, L., Nordgren, H., and Bergh, A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth, and survival. Urol. Res., 24: 257-264, 1996.
9. Witjes, W. P., Oosterhof, G. O., Schaafsma, H. E., and Debruyne, F. M. Current status of neoadjuvant therapy in localized prostate cancer. Prostate, 27: 297-303, 1995.
10. Jewett, H. J. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol. Clin. North Am., 2: 105-124, 1975.
11. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J., Scheper, R. J., and Zaman, G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557-4563, 1994.
12. r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res., 54: 5788-5792, 1994.
13. Guinee, D. G., Jr., Holden, J. A., Benfield, J. R., Woodward, M. L., Przygodzki, R. M., Fishback, N. F., Koss, M. N., and Travis, W. D. Comparison of DNA topoisomerase II α expression in small cell and non-small cell carcinoma of the lung: in search of a mechanism of chemotherapeutic response. Cancer (Phila.), 78: 729-735, 1996.
14. Lohri, A., Reuter, J., Gudat, F., and Herrmann, R. Topoisomerase II α mRNA and tumour cell proliferation in non-Hodgkin's lymphoma, J. Clin. Pathol. (Lond.), 50: 22-26, 1997.
15. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151: 237-244, 1992.
16. Bartek, J., Bartkova, J., Lukas, J., Staskova, Z., Vojtesek, B., and Lane, D. P. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol., 169: 27-34, 1993.
17. Vojtesek, B., Fisher, C. J., Barnes, D. M., and Lane, D. P. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br. J. Cancer, 67: 1254-1258, 1993.
18. Lane, D. P., Stephen, C. W., Midgley, C. A., Sparks, A., Hupp, T. R., Daniels, D. A., Greaves, R., Reid, A., Vojtesek, B., and Picksley, S. M. Epitope analysis of the murine p53 tumour suppressor protein. Oncogene, 12: 2461-2466, 1996.
19. Cairns, J., Wright, C., Cattan, A. R., Hall, A. G., Cantwell, B. J., Harris, A. L., and Home, C. H. Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J. Pathol., 166: 19-25, 1992.
20. Kodate, C., Fukushi, A., Narita, T., Kudo, H., Soma, Y., and Sato, K. Human placental form of glutathione S-transferase (GST-pi) as a new immunohistochemical marker for human colonie carcinoma. Jpn. J. Cancer Res., 77: 226-229, 1986.
21. Harrison, D. J., Kharbanda, R., Bishop, D., McLelland, L. I., and Hayes, J. D. Glutathione S-transferase isoenzymes in human renal carcinoma demonstrated by immunohistochemistry. Carcinogenesis (Lond.), 10: 1257-1260, 1989.
22. Pezzella, F., Jones, M., Ralfkiaer, E., Ersboll, J., Gatter, K. C., and Mason, D. Y. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br. J. Cancer, 65: 87-89, 1992.
23. Scheper, R. J., Bulte, J. W., Brakkee, J. G., Quak, J. J., van der Schoot, E., Balm, A. J., Meijer, C. J., Broxterman, H. J., Kuiper, C. M., Lankelma, J., and Pinedo, H. M. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int. J. Cancer, 42: 389-394, 1988.
24. Schinkel, A. H., Roelofs, E. M., and Borst, P. Characterization of the human MDR3 P-Glycoprotein and its recognition by P-Glycoprotein-specific monoclonal antibodies. Cancer Res., 51: 2628-2635, 1991.
25. Toth, K., Vaughan, M. M., Slocum, H. K., Arredondo, M. A., Takita, H., Baker, R. M., and Rustum, Y. M. New immunohistochemical "sandwich" staining method for mdrl P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am. J. Pathol., 144: 227-236, 1994.
26. Armitage, P., and Berry, G. Statistical Methods in Medical Research, 3rd ed., p. 429. London: Blackwell Scientific Publishers, 1994.
27. Ingelfinger, J. A., Mosteller, F., Thibodeau, L. A., and Ware, J. H. Biostatistics in Clinical Medicine, 3rd ed., pp. 316-317. New York: McGraw-Hill, Inc., 1994.
28. Flens, M. J., Zaman, G. J., van der Valk, P., Izquierdo, M. A., Schroeijers, A. B., Scheffer, G. L., van der Groep, P., de Haas, M., Meijer, C. J., and Scheper, R. J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol., 148: 1237-1247, 1996.
29. Hu, J., Wang, Z., and Jiang, Y. Relations between p53 and p185 expression and prognosis of patients with colon cancers (in Chinese). Chung Hua Chung Liu Tsa Chih, 18: 247-249, 1996.
30. Terrier, P., Townsend, A. J., Coindre, J. M., Triche, T. J., and Cowan, K. H. An immunohistochemical study of π-class glutathione S-transferase expression in normal human tissue. Am. J. Pathol., 137: 845-853, 1990.
31. Bittl, A., Nap, M., Jager, W., Cornillie, F., and Lang, N. Immunohistochemical detection of P-glycoprotein on frozen and paraffin- embedded tissue sections of normal and malignant tissues. Anticancer Res., 15: 1007-1014, 1995.
32. Cole, S. P., and Deeley, R. G. Multidrug resistance associated with overexpression of MRP. Cancer Treat. Res., 87: 39-62, 1996.
33. Lautier, D., Canitrot, Y., Deeley, R. G., and Cole, S. P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol., 52: 967-977, 1996.
34. Nooter, K., and Stoter, G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract., 192: 768-780, 1996.
35. D'Arpa, P., and Liu, L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989: 163-177, 1989.
36. Boege, F. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects. Eur. J. Clin. Chem. Clin. Biochem., 34: 873-888, 1996.
37. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F., and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50: 7962-7965, 1990.
38. Chatterjee, D., Wyche, J. H., and Pantazis, P. Induction of apoptosis in malignant and camptothecin-resistant human cells. Ann. NY Acad. Sci., 803: 143-156, 1996.
39. Pienta, K. J., and Lehr, J. E. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J. Urol., 149: 1622-1625, 1993.
40. Hudes, G. R., Kosierowski, R., Greenberg, R., Ramsey, H. E., Fox, S. C., Ozols, R. F., McAleer, C. A., and Giantonio, B. J. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest. New Drugs, 13: 235-240, 1995.
41. Fuse, H., Muraishi, Y., Fujishiro, Y., and Katayama, T. Etoposide, epirubicin, and carboplatin in hormone-refractory prostate cancer. Int. Urol. Nephrol., 28: 79-85, 1996.
42. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756-1764, 1996.
43. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
44. Murphy, M., Hinman, A., and Levine, A. J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev., 10: 2971-2980, 1996.
45. McDonnell, T. J., Meyn, R. E., and Robertson, L. E. Implications of apoptotic cell death regulation in cancer therapy. Semin. Cancer Biol., 6: 53-60, 1995.
46. Chresta, C. M., Arriola, E. L., and Hickman, J. A. Apoptosis and cancer chemotherapy. Behring Inst. Mitt., 97: 232-240, 1996.
47. Zhang, C. C., Yang, J-M., White, E., Murphy, M., Levine, A., and Hait, W. N. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to Vinca alkaloids in p53 mutant cells. Oncogene, 16: 1617-1624, 1998.
48. Brewster, S. F., Browne, S., and Brown, K. W. Somatic allelic loss at the DCC, APC, nm23-H1, and p53 tumor suppressor gene loci in human prostatic carcinoma. J. Urol., 151: 1073-1077, 1994.
49. Mottaz, A. E., Markwalder, R., Fey, M. F., Klima, I., Merz, V. W., Thalmann, G. N., Ball, R. K., and Studer, U. E. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate, 31: 209-215, 1997.
50. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814-3822, 1996.
51. Cohen, R. J., Cooper, K., Haffejee, Z., Robinson, E., and Becker, P. J. Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology, 27: 229-232, 1995.
52. Stattin, P., Bergh, A., Karlberg, L., Nordgren, H., and Damber, J. E. p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur. Urol., 30: 65-72, 1996.
53. Moyret-Lalle, C., Marcais, C., Jacquemier, J., Moles, J. P., Daver, A., Soret, J. Y., Jeanteur, P., Ozturk, M., and Theillet, C. ras, p53, and HPV status in benign and malignant prostate tumors. Int. J. Cancer, 64: 124-129, 1995.
54. Lutzker, S. G., and Levine, A. J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med., 2: 804-810, 1996.
55. Midgley, C. A., and Lane, D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene, 15: 1179-1189, 1997.
56. Rahilly, M., Carder, P. J., al Nafussi, A., and Harrison, D. J. Distribution of glutathione S-transferase isoenzymes in human ovary. J. Reprod. Fertil., 93: 303-311, 1991.
57. Cappellen, D., and Benard, J. Pleiotropic over-expression of multidrug resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model. Int. J. Cancer, 70: 430-436, 1997.
58. Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., Hsieh, W. S., Isaacs, W. B., and Nelson, W. G. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA, 91: 11733-11737, 1994.
59. McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., and Korsmeyer, S. J. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57: 79-88, 1989.
60. Harms-Ringdahl, M., Nicotera, P., and Radford, I. R. Radiation induced apoptosis. Mutat. Res., 366: 171-179, 1996.
61. McConkey, D. J., Chandra, J., Wright, S., Plunkett, W., McDonnell, T. J., Reed, J. C., and Keating, M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J. Immunol., 156: 2624-2630, 1996.
62. Cardillo, M., Berchem, G., Tarkington, M. A., Krajewski, S., Krajewski, M., Reed, J. C., Tehan, T., Ortega, L., Lage, J., and Gelmann, E. P. Resistance to apoptosis and up-regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J. Urol., 158: 212-216, 1997.
63. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Bauer, J. J. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery (St. Louis), 120: 159-166, 1996.
64. Furuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C., and Isaacs, J. T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res., 2: 389-398, 1996.
65. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1576, 1996.
66. Akimoto, S., Akakura, K., Masai, M., and Shimazaki, J. Response to chemotherapy in endocrine therapy-relapsed and -resistant prostate cancer (in Japanese). Hinyokika Kiyo, 37: 31-37, 1991.
67. Keppler, D., Leier, I., and Jedlitschky, G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem., 378: 787-791, 1997.